Lifitegrast in Treatment of Dry Eye Disease—A Practical, Narrative Expert Review
Conclusions: Based on the current literature, we conclude that lifitegrast could improve various parameters of DED. Still, larger controlled trials are required to establish additional benefits of this medication beyond those of other DED treatments.
Saved in:
Main Authors: | Erlend C. S. Landsend, Mads Istre, Tor P. Utheim |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2025-01-01
|
Series: | Journal of Ophthalmology |
Online Access: | http://dx.doi.org/10.1155/joph/6504111 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Therapeutic Potential of Combined 5% Lifitegrast and Tocopherol Eye Drops in Managing Inflammation and Oxidative Stress in Murine Dry Eye
by: Jayoung Moon, et al.
Published: (2025-01-01) -
Change in Ocular Surface Staining during Eyelid Warming Is Related to Tear Cytokine Levels
by: Erlend C. S. Landsend, et al.
Published: (2022-01-01) -
Dry Eye Disease and Refractive Corrections
by: David Madrid-Costa, et al.
Published: (2019-01-01) -
The Dry Eye Disease Activity Log Study
by: Jayant V. Iyer, et al.
Published: (2012-01-01) -
Objective Imaging Diagnostics for Dry Eye Disease
by: Sang Beom Han, et al.
Published: (2020-01-01)